Positioning political buying, disclosed 2026-09-25
Options put/call open interest 3.13, read 2026-10-23
Ethical does not pass the values gate
Price43.02 USD
Fair value52.50
Ethical score10.0/100
RatingAVOID
Our investment reviews on this name
2026-10-21Read Markdown40.63+5.9% to today Distribution gives way to Markdown after a 16% slide in 3 weeks
2026-10-02Read Distribution48.47-11.2% to today ✓Markup gives way to Distribution after a 5% slide in 13 weeks
2026-07-02Read Markup51.28-16.1% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Alexandria Real Estate Equities holds its Distribution at $43.02. Consolidating, no directional conviction, held for 88 days.
As held on the ledger · 2026-10-23
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 88 days
Price at the screen
$43.02
Valuation
N/A trailing · -50.16 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.18
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
37.44%
Below 33%
Interest-bearing debt is 37.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
4.49%
Below 33%
Cash held in interest-bearing accounts and securities is 4.5% of assets, under the one-third limit.
Pass
Receivables
1.63%
Below 49%
Money owed to the company is 1.6% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Alexandria Real Estate Equities's business is in a permissible area, but its interest-bearing debt is about 37% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ARE's ethical verdict changes
Today ARE does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads AVOID: it trades at roughly a 29% discount to our $52.50 fair value, weak competitive moat.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 29.2% margin of safety to the base estimate.
Third-party analyst targets: 14 covering, consensus Hold. The average target sits +22% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Life science landlord posts deepening losses
Picture a landlord whose lab buildings should be in demand yet still reports shrinking revenue and negative profits. We pass on this name because the core numbers point to a business losing ground fast in a sector that demands strength.
Forward earnings sit at a negative fifty seven times multiple with revenue down twelve percent and profit margins at negative thirty six percent. Return on equity has turned negative four percent while the ethical screen flags excessive debt and the moat looks weak.
Fourteen analysts sit on a hold rating with a median target only slightly above the current price yet the combination of leverage and negative returns leaves little room for error if rates stay high. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ARE trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-26Markdown$40.63+0.0%Entry 17
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 23%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it hold, with a mean price target of $51. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$40.63+0.0%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 23%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it hold, with a mean price target of $51. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markdown$40.63+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 23%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it hold, with a mean price target of $51. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markdown$40.63+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 23%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it hold, with a mean price target of $51. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markdown$40.63+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 23%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it hold, with a mean price target of $51. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown · changed$40.63+0.0%Entry 12
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 23%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it hold, with a mean price target of $51. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Distribution$40.63-4.0%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 23%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it hold, with a mean price target of $51. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Distribution$42.34-7.0%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are down 23%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it hold, with a mean price target of $51. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-12Distribution$45.51-6.1%Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 23%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it hold, with a mean price target of $51.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 9.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 23%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it hold, with a mean price target of $51.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
